Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
A method of treating a disease or condition in a subject in need thereof is disclosed. The method comprising: trans-epithelially administering a dispensable substance to the gastrointestinal (GI) tract of the subject by orally administering an ingestible device comprising the dispensable substance to the subject. The ingestible device is configured for trans-epithelial delivery of the dispensable substance to the GI tract of the subject and the dispensable substance comprises a pharmaceutical formulation comprising a therapeutically effective amount of a glucagon receptor agonist or a glucagon-like peptide-1 (GLP-1) receptor agonist. The ingestible device releases the dispensable substance as at least one jet to a desired location of the GI tract of the subject.
1. A method of treating a disease or condition in a subject in need thereof, the method comprising: trans-epithelially administering a dispensable substance to the gastrointestinal (GI) tract of the subject, wherein the trans-epithelial administration comprises: orally administering an ingestible device comprising the dispensable substance to the subject, wherein the ingestible device is configured for trans-epithelial delivery of the dispensable substance to the GI tract of the subject, and the dispensable substance comprises a pharmaceutical formulation comprising a therapeutically effective amount of a glucagon receptor agonist or a glucagon-like peptide-1 (GLP-1) receptor agonist; and releasing the dispensable substance from the ingestible device as at least one jet to a desired location of the GI tract of the subject; wherein the desired location of the GI tract is the small intestine, wherein the trans-epithelial administration directly delivers the dispensable substance to the submucosa of the GI tract of the subject, and wherein the disease or condition is responsive to treatment with the glucagon receptor agonist or GLP-1 receptor agonist.
2. The method of claim 1 , wherein the trans-epithelial administration provides systemic uptake of the glucagon receptor agonist or the GLP-1 receptor agonist that is at least about 20% relative to intravenous or subcutaneous administration of an equal amount of the glucagon receptor agonist or the GLP-1 receptor agonist.
3. The method of claim 1 , wherein the glucagon receptor agonist or the GLP-1 receptor agonist has a molecular weight of at least about 1.5 kDa.
4. The method of claim 1 , wherein the desired location of the GI tract is the jejunum.
5. The method of claim 1 , wherein the trans-epithelial administration provides systemic uptake of the glucagon receptor agonist or the GLP-1 receptor agonist that is at least about 10% relative to intravenous or subcutaneous administration of an equal amount of the glucagon receptor agonist or the GLP-1 receptor agonist.
6. The method of claim 1 , wherein the trans-epithelial administration provides an area under the curve (AUC) of the glucagon receptor agonist or the GLP-1 receptor agonist in systemic circulation over time (AUC TE ) that is at least about 10% of the AUC in systemic circulation over time provided by intravenous administration of an equal amount of the glucagon receptor agonist or the GLP-1 receptor agonist (AUC IV ) or by subcutaneous administration of an equal amount of the glucagon receptor agonist or the GLP-1 receptor agonist (AUC SC ).
7. The method of claim 1 , wherein the trans-epithelial administration provides a maximum plasma concentration (C max ) of the glucagon receptor agonist or the GLP-1 receptor agonist in systemic circulation ((C max ) TE ) that is at least about 10% of the C max in systemic circulation provided by intravenous administration of an equal amount of the glucagon receptor agonist or the GLP-1 receptor agonist ((C max ) IV ) or by subcutaneous administration of an equal amount of the glucagon receptor agonist or GLP-1 receptor agonist ((C max ) SC ).
8. The method of claim 1 , wherein the pharmaceutical formulation is a liquid solution or suspension.
9. The method of claim 1 , wherein a volume of the dispensable substance released from the ingestible device is from about 50 microliters to about 800 microliters.
10. The method of claim 1 , wherein releasing the dispensable substance from the ingestible device as at least one jet to a desired location of the GI tract of the subject is at a peak jet power of about 1 Watt to about 3 Watts.
11. The method of claim 1 , wherein the disease or condition is a metabolic, endocrine, or cardiovascular disease or condition.
12. The method of claim 11 , wherein the metabolic or endocrine disease or condition is selected from the group consisting of diabetes, a liver disease or disorder, obesity, hyperglycemia, hyperlipidemia, hyperinsulinemia, hypercholesterolemia, lipodystrophy, obstructive sleep apnea, nicotine dependence, and a central nervous system (CNS) disorder.
13. The method of claim 12 , wherein the liver disease or disorder is selected from the group consisting of compensated liver cirrhosis, liver fibrosis, non-alcoholic steatohepatitis (NASH), and non-alcoholic fatty liver disease (NAFLD).
14. The method of claim 11 , wherein the cardiovascular disease or condition is selected from the group consisting of myocardial infarction, stroke, coronary artery diseases (CAD), heart failure, transient ischemic attacks, peripheral arterial disease, aortic disease, aortic aneurysms, congestive heart failure, hypertension, hypertensive heart disease, pulmonary artery hypertension, arrhythmia, and thromboembolism.
15. The method of claim 1 , wherein the glucagon receptor agonist or the GLP-1 receptor agonist has a molecular weight of from about 1.5 kDa to about 5 kDa.
16. The method of claim 1 , wherein the glucagon receptor agonist or the GLP-1 receptor agonist is selected from the group consisting of semaglutide, dulaglutide, cotadutide, exenatide, liraglutide, tirzepatide, NNC-0090-2746, glucagon, NN-9277, and NN-9423; and biosimilars thereof.
17. The method of claim 16 , wherein the glucagon receptor agonist or the GLP-1 receptor agonist is cotadutide or a biosimilar thereof.
18. The method of claim 16 , wherein the glucagon receptor agonist or the GLP-1 receptor agonist is liraglutide or a biosimilar thereof.
19. The method of claim 16 , wherein the glucagon receptor agonist or the GLP-1 receptor agonist is tirzepatide or a biosimilar thereof.
20. A method of treating a disease or condition in a patient, comprising:
trans-epithelially administering a pharmaceutical formulation to the gastrointestinal tract of patient via the patient swallowing an ingestible device containing the pharmaceutical formulation;
the ingestible device configured for trans-epithelial delivery of the pharmaceutical formulation to the gastrointestinal tract;
the pharmaceutical formulation comprising a therapeutically effective amount of a glucagon receptor agonist or a glucagon-like peptide-1 receptor agonist; and
releasing the pharmaceutical formulation from the ingestible device in the small intestine as one or more jets to directly deliver the pharmaceutical formulation to the submucosa of the gastrointestinal tract.
21. The method of claim 20 wherein the trans-epithelial administration provides systemic uptake of the glucagon receptor agonist or the GLP-1 receptor agonist that is at least about 25% of the systemic uptake of intravenous or subcutaneous administration of an equal amount of glucagon receptor agonist or GLP-1 receptor agonist.
22. The method of claim 20 wherein the trans-epithelial administration provides an area under the curve (AUC) of the glucagon receptor agonist or the GLP-1 receptor agonist in systemic circulation over time (AUC TE ) that is at least about 25% of the AUC in systemic circulation over time provided by intravenous administration of an equal amount of glucagon receptor agonist or GLP-1 receptor agonist (AUC IV ) or by subcutaneous administration of an equal amount of glucagon receptor agonist or GLP-1 receptor agonist (AUC sc ).
23. The method of claim 20 wherein the trans-epithelial administration provides a maximum plasma concentration (C max ) of the glucagon receptor agonist or the GLP-1 receptor agonist in systemic circulation ((C max ) TE ) that is at least about 25% of the C max in systemic circulation provided by intravenous administration of an equal amount of glucagon receptor agonist or GLP-1 receptor agonist ((C max ) IV ) or by subcutaneous administration of an equal amount of glucagon receptor agonist or GLP-1 receptor agonist ((C max ) SC ).
24. The method of claim 20 wherein a volume of the pharmaceutical formulation released from the ingestible device is about 250 microliters to about 400 microliters.